Adavivint

Adavivint (SM04690; Lorecivivint) is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells[1].

Product Specifications

CAS Number

[1467093-03-3]

Product Name Alternative

SM04690; Lorecivivint

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Wnt

Type

Reference compound

Related Pathways

Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Adavivint.html

Purity

98.85

Solubility

DMSO : 25 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL

Smiles

CC(C)CC(NC1=CC(C2=CC3=C(NN=C3C(N4)=NC5=C4C(C6=CC=CC(F)=C6)=CN=C5)C=C2)=CN=C1)=O

Molecular Formula

C29H24FN7O

Molecular Weight

505.55

Precautions

H302, H315, H319, H335

References & Citations

[1]Deshmukh V, et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2018 Jan;26 (1) :18-27.